Medicine and Dentistry
Peripheral T-Cell Lymphoma
100%
Myeloproliferative Neoplasm
24%
Neoplasm
20%
CHOP
20%
Cancer
17%
Anaplastic Large Cell Lymphoma
16%
Immunohistochemistry
15%
Clinical Trial
13%
Overall Survival
13%
Proteomics
12%
Predictive Marker
12%
Galectin 1
12%
Positron Emission Tomography-Computed Tomography
12%
Adverse Outcome
12%
Digital Pathology
12%
Cohort Effect
12%
Tissue Microarray
12%
Langerhans Cell Histiocytosis
12%
Janus Kinase
12%
Myeloid metaplasia
12%
Targeted Therapy
12%
Cutaneous T Cell Lymphoma
12%
Disease
10%
T-Cell Lymphoma
10%
Radiation Therapy
9%
Alemtuzumab
9%
Anaplastic Lymphoma Kinase
7%
B Symptoms
7%
Mogamulizumab
7%
Brentuximab Vedotin
7%
Transcription Factor T Bet
6%
International Prognostic Index
5%
Biopsy
5%
Protein Expression
5%
Biochemistry, Genetics and Molecular Biology
T Cell
31%
CD30
20%
Peripheral T-Cell Lymphoma Not Otherwise Specified
12%
Surface Property
12%
PD-L1
12%
Immune Checkpoints
12%
STAT3
12%
DNA Methylation
12%
Complement Activation
12%
Proteomics
12%
Galectin-1
12%
Digital Pathology
12%
Gene Expression Profiling
9%
Peptidoglycan
8%
Overall Survival
8%
Tyrosine Kinase
6%
Demethylating Agent
6%
DNA Hypomethylation
6%
Protein Microarray
6%
CD58
6%
Antigenicity
6%
Receptor Tyrosine Kinase
6%
DNA Demethylation
6%
Gene Signature
6%
TBX21
5%
Immunoglobulin M
5%
Keyphrases
Genetic Modification
12%
Same Patient
12%
Lymphoid Malignancies
12%
Lymphoma
12%
Molecular Subclassification
12%
Peripheral T-cell lymphoma-NOS
12%
Predictive Marker
12%
Myeloproliferative Neoplasms
12%
Tumor
12%
Systemic Targeted Therapy
12%
Relapsed or Refractory
12%
Advanced Stage
12%
Single Center
12%
Cutaneous T-cell Lymphoma
12%
Alemtuzumab
9%
Mogamulizumab
7%
Brentuximab Vedotin
7%
GATA3
6%
TBX21
6%